Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Molecular imaging of cardiovascular disease using ultrasound

Ultrasound Molecular Imaging: Principles and Applications in Cardiovascular Medicine

Molecular ultrasound imaging: current status and future directions

Advance in Ultrasound Molecular Imaging

Advances in Molecular Targeted Ultrasound Contrast Agents

Functional and Molecular Ultrasound Imaging: Concepts and Contrast Agents

Advances in ultrasound molecular imaging

In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development

Ultrasound Microbubbles for Molecular Diagnosis, Therapy, and Theranostics

Ultrasound Microbubbles for Diagnosis and Treatment of Cardiovascular Diseases

The Advent of Biomolecular Ultrasound Imaging

New Progress in Ultrasound Molecular Imaging

Progress of targeted ultrasound contrast agents in cardiovascular disease

Molecular Imaging of Atherosclerotic Plaque with Lipid Nanobubbles As Targeted Ultrasound Contrast Agents

Applications of Ultrasound Targeted Micro/Nano Probes and Intelligent Ultrasound Molecular Imaging Technology

Molecular imaging nanoprobes and their applications in atherosclerosis diagnosis

Ultrasound Molecular Imaging of Atherosclerosis for Early Diagnosis and Therapeutic Evaluation through Leucocyte-like Multiple Targeted Microbubbles.

Multimodality Molecular Imaging of Cardiovascular Disease Based on Nanoprobes

Molecular Image-Guided Theranostic and Personalized Medicine 2013

Microbubbles and ultrasound: from diagnosis to therapy